WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H584337
CAS#: 36556-75-9
Description: Bucumarol a beta-adrenergic blocking agent, on blood pressure and the renin angiotensin system were studied in spontaneously hypertensive rats (SHR).
Hodoodo Cat#: H584337
Name: Bucumarol (HCl)
CAS#: 36556-75-9
Chemical Formula: C17H24ClNO4
Exact Mass: 341.14
Molecular Weight: 341.832
Elemental Analysis: C, 59.73; H, 7.08; Cl, 10.37; N, 4.10; O, 18.72
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 525-66-6 (free base)
Synonym: Bucumarol; CS 359
IUPAC/Chemical Name: 2H-1-Benzopyran-2-one, 8-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-5-methyl-, hydrochloride, (+-)-
InChi Key: OQVOZUWFVLLPRL-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H23NO4.ClH/c1-11-5-7-14(16-13(11)6-8-15(20)22-16)21-10-12(19)9-18-17(2,3)4;/h5-8,12,18-19H,9-10H2,1-4H3;1H
SMILES Code: O=C1C=CC2=C(C)C=CC(OCC(O)CNC(C)(C)C)=C2O1.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 341.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Hayashi R, Okada M, Nakazawa T, Tanaka Y, Shimoji Y. Metabolic studies on CS-359, a new beta-adrenergic blocking agent. I. Isolation and identification of the urinary metabolites of CS-359. Chem Pharm Bull (Tokyo). 1975 Jun;23(6):1173-83. PubMed PMID: 241498.
2: Kumakura S, Oshima T. Effects of beta blockers on cardiac function and myocardial oxygen consumption in the isolated supported heart preparation of the dog. Jpn Heart J. 1975 Sep;16(5):592-602. PubMed PMID: 240050.
3: Oshima T, Kumakura S, Koike H, Nakayama K. Pharmacology of dl-5-methyl-8-(2-hydroxy-3-t-butylaminopropoxy) coumarin hydrochloride (CS-359), a new beta-adrenergic blocking agent. Jpn J Pharmacol. 1973 Aug;23(4):497-513. PubMed PMID: 4148384.
4: Kubota M, Gotho Y, Furukawa K. [Cardiovascular effects of propanolol, alprenolol, oxprenolol and CS-359 during halothane anesthesia (author's transl)]. Masui. 1979 Aug;28(8):797-804. Japanese. PubMed PMID: 43404.
5: Gurol-Urganci I, Cromwell DA, Edozien LC, Smith GC, Onwere C, Mahmood TA, Templeton A, van der Meulen JH. Risk of placenta previa in second birth after first birth cesarean section: a population-based study and meta-analysis. BMC Pregnancy Childbirth. 2011 Nov 21;11:95. doi: 10.1186/1471-2393-11-95. PubMed PMID: 22103697; PubMed Central PMCID: PMC3247856.
6: Nakayama K, Oshima T, Koike H. Antiarrhythmic activity of dextro- and levo-isomers of 5-methyl-8-(2-hydroxy-3-t-butylamino-propoxy) coumarin hydrocholoride (bucumolol), a beta-adrenergic blocking agent, on aconitine-induced atrial and ouabain-induced ventricular arrhythmias in dogs. Jpn J Pharmacol. 1979 Dec;29(6):935-45. PubMed PMID: 44326.
7: Nakayama K, Oshima T, Koike H. Assessment of beta-blockade and the non-specific effect of bucumolol, a beta-adrenergic blocking agent, on atrioventricular conduction in anesthetized dogs. Arch Int Pharmacodyn Ther. 1981 Nov;254(1):145-56. PubMed PMID: 6121536.
8: Miyamoto M, Koike H, Ito K, Nishino H. Antihypertensive activity of bucumolol, a beta-adrenergic blocking agent, in spontaneously hypertensive rats. J Pharmacobiodyn. 1981 Jul;4(7):455-60. PubMed PMID: 6117610.
9: Koike H, Kumakura S, Nishino H, Tamaoki H, Minato S. Effects of bucumolol, a beta-adrenergic blocking agent, and its d-isomer on myocardial infarction produced by coronary artery ligation in rats. Jpn Heart J. 1981 Sep;22(5):815-23. PubMed PMID: 6119377.
10: Ichiyama M, Sada S, Takahashi Y, Sada H, Ban T. Effects of bucumolol, nadolol and nifenalol on maximum upstroke velocity of action potential in guinea pig papillary muscles. Naunyn Schmiedebergs Arch Pharmacol. 1986 Mar;332(3):297-304. PubMed PMID: 2872598.
11: Miyazaki M, Muranishi R, Yokono S. Clinical and experimental studies on a new beta-adrenergic blocker. Use of dl-5-methyl-8-(2-hydroxy-3-t-butylaminopropoxy) coumarin hydrochloride (bucumolol) in anesthesia. Med J Osaka Univ. 1977 Mar;27(3-4):129-53. PubMed PMID: 24799.
